EFSA statement on the requirements for whole genome sequence analysis of microorganisms intentionally used in the food chain
Microorganisms, genetically modified or not, may be used in the food chain as such or as production organisms of substances of interest. The placement of such microorganisms or derived substances/products in the European market may be subject to a pre‐market authorisation process. The authorisation...
Saved in:
Published in | EFSA journal Vol. 19; no. 7; pp. e06506 - n/a |
---|---|
Format | Journal Article |
Language | English |
Published |
United States
John Wiley & Sons, Inc
01.07.2021
John Wiley and Sons Inc Wiley |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Microorganisms, genetically modified or not, may be used in the food chain as such or as production organisms of substances of interest. The placement of such microorganisms or derived substances/products in the European market may be subject to a pre‐market authorisation process. The authorisation process defines the need to perform a risk assessment to establish the safety and/or the efficacy of the microorganisms when used in the food chain as such or as production strains of substances of interest. In order to perform a risk assessment, the microorganism/s subject to the application for authorisation need/s to be characterised. In this regard, data obtained from whole genome sequence analysis can provide information on the unequivocal taxonomic identification of the strains and on the characterisation of their potential functional traits of concern which may include virulence factors, resistance to antimicrobials of clinical relevance for humans and animals, production of known toxic metabolites. In fact, in some areas of the regulated products, the use of whole genome sequence‐based data has been established as a requirement for the risk assessment. This document provides recommendations to applicants on how to describe the process and results which should be provided to the risk assessor in the context of an application for market authorisation of a regulated product. Indications are given on how to perform WGS and the quality criteria/thresholds that should be reached as well as the data and relevant information that need to be sent along whenever such kind of data is required. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Requestor: EFSA Question number: EFSA‐Q‐2019‐00434 Declarations of interest: The declarations of interest of all scientific experts active in EFSA's work are available at https://ess.efsa.europa.eu/doi/doiweb/doisearch. Acknowledgements: On 18 February 2021 the Scientific Committee of EFSA endorsed this Statement (except Annex A). EFSA wishes to acknowledge the contribution of Philip Ashton, Joao Andre Carriço (until August 2019), Christina Cuomo and Baltasar Mayo to the drafting of this EFSA statement, and the contribution from EFSA experts from FEEDAP, CEP and NDA Panels including: Andrew Chesson, Henrik Christensen, Pier Sandro Cocconcelli, Boet Glandorf, Lieve Herman, Carmen Pelaez, Miguel Prieto Maradona, Maria Saarela, Yolanda Sanz and Laurence Vernis. EFSA also wishes to acknowledge the contribution of EFSA staff from APDESK, FEED, FIP, GMO, NUTRI, PREV and DATA Units and Scientific Committee including: Reinhard Ackerl, Jaime Aguilera, Montserrat Anguita, Rosella Brozzi, Laszlo Bura, Silvia Federici, Ana Gomes, Beatriz Guerra, Giovanni Iacono, Frederique Istace, Dimitra Kardassi, Nikoletta Papadopoulou, Elisa Pettenati, Patricia Romero, Reinhilde Schoonjans and Frank Verdonck. EFSA also acknowledges the participation of Louis Edward as a hearing expert. Already published on of EFSA website on 10 March 2021. Adopted: 2 March 2021 |
ISSN: | 1831-4732 1831-4732 |
DOI: | 10.2903/j.efsa.2021.6506 |